Concord Drugs Share Price | Concord Drugs Stock Screener
CONCORD
Pharmaceuticals
Share Price BSE
₹77.45
▲
1.37 (1.80%)
As of July 3, 2026, the Concord Drugs share price (BSE: CONCORD) is ₹77.45, up 1.80% from the previous close, with shares trading between ₹76.63 and ₹77.50, and a 52-week range of ₹49.10–₹90.08.
Analyse CONCORD stock price history and track historical price performance.
Use the Concord Drugs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Concord Drugs Market Cap
₹98.83 Cr.
CONCORD P/E Ratio (TTM)
96.19
Concord Drugs P/B Ratio
2.09
EPS (TTM)
₹0.95
Dividend Yield
-
Debt to Equity
0.54
CONCORD 52 Week High
₹90.08
Concord Drugs 52 Week Low
₹49.10
Operating Margin
4.00%
Profit Margin
2.63%
CONCORD Revenue (TTM)
₹38.00
EBITDA
₹2.00
Net Income
₹1.00
Total Assets
₹75.00
Total Equity
₹49.00
Concord Drugs Share Price Chart
Screen Concord Drugs share price with an interactive chart. Analyse CONCORD price trends and volatility across different timeframes.
Concord Drugs Company Profile - Fundamental Screener
Screen Concord Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for CONCORD shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE858L01010
Concord Drugs Balance Sheet Screener
Screen CONCORD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 75 | 65 | 59 | 58 | 56 |
| Current Assets | 53 | 41 | 38 | 44 | 42 |
| Fixed Assets | 14 | 12 | 12 | 13 | 14 |
| Liabilities | |||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 5 | 5 | 4 | 5 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 49 | 34 | 34 | 32 | 28 |
| Share Capital | 13 | 10 | 10 | 9 | 9 |
| Reserves & Surplus | 35 | 24 | 24 | 22 | 20 |
Concord Drugs Income Statement Screener - Profit & Revenue Analysis
Screen Concord Drugs income statement and profit fundamentals.
Analyze CONCORD quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Concord Drugs share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38 | 17 | 10 | 14 | 10 | 11 | 12 | 12 | 16 | 13 | 8 | 9 | 12 | 14 | 14 |
| Expenses | 36 | 16 | 9 | 13 | 9 | 9 | 12 | 11 | 15 | 12 | 6 | 8 | 11 | 12 | 13 |
| EBITDA | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 1 | 1 | 1 |
| Operating Profit % | 4.00% | 5.00% | 11.00% | 7.00% | 10.00% | 13.00% | 7.00% | 7.00% | 2.00% | 5.00% | 21.00% | 16.00% | 8.00% | 11.00% | 9.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Profit Before Tax | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | -1 | 0 | 1 | 1 | 0 | 1 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| EPS | 0.47 | 0.16 | 0.19 | 0.12 | 0.04 | 0.23 | 0.04 | 0.03 | -0.34 | -0.24 | 0.60 | 0.53 | 0.17 | 0.52 | 0.21 |
Concord Drugs Cash Flow Screener - Liquidity Fundamentals
Screen CONCORD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | 4 | 1 | 2 | 1 |
| Investing Activities | -2 | -1 | -2 | -2 |
| Financing Activities | -1 | 0 | 1 | 2 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
Concord Drugs Shareholding Pattern Screener
See Concord Drugs shareholding pattern with promoter, FII, and DII holdings.
Check Concord Drugs promoter holding and ownership changes for CONCORD on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Nov | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.39% | 54.39% | 54.39% | 54.39% | 45.08% | 54.39% | 55.41% | 55.41% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 44.66% | 43.33% | 42.57% | 44.95% | 54.43% | 44.96% | 44.28% | 44.30% |
| Other Holding | 0.94% | 2.28% | 3.04% | 0.66% | 0.49% | 0.65% | 0.31% | 0.29% |
| Shareholder Count | 4,464 | 5,252 | 5,189 | 4,718 | 4,597 | 4,597 | 4,734 | 4,755 |
Concord Drugs Share Dividend Screener - Share Yield Analysis
Check Concord Drugs dividend history with payout and yield data.
View Concord Drugs dividend details including ex-dates and amounts for CONCORD stock.
Concord Drugs Stock Index Membership
See which indices include Concord Drugs stock.
Check CONCORD index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Concord Drugs Market Events Screener - Corporate Actions
Get Concord Drugs corporate actions including splits, bonuses, and buybacks.
Check Concord Drugs stock events that may affect CONCORD share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -4.66% | ||
| Annual General Meeting | NA | -1.64% | ||
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 0.96% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | 16.05% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 31.55% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -2.24% |
| 2025-07-31 | 2025-07-31 | Extraordinary General Meeting | NA | 0.94% |
| 2025-07-30 | 2025-07-30 | Extraordinary General Meeting | NA | 8.84% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | -0.03% |
| 2025-01-11 | 2025-01-11 | Quarterly Result Announcement | NA | -1.79% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -3.25% |
Concord Drugs Competitors Screener - Peer Comparison
Screen CONCORD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,675 | 39.04 | 58,220 | 6.38% | 11,565 | 65.03 |
| Divis Laboratories | 174,864 | 67.84 | 10,560 | 8.73% | 2,520 | 43.32 |
| Torrent Pharmaceuticals | 157,225 | 73.76 | 13,886 | 20.34% | 2,138 | 66.05 |
| Cipla | 118,333 | 30.41 | 29,045 | 2.24% | 3,870 | 68.02 |
| Dr Reddys Laboratories | 113,256 | 27.63 | 33,593 | -0.44% | 3,998 | 73.77 |
| Zydus Life Science | 112,296 | 22.03 | 26,720 | 13.65% | 5,242 | 66.06 |
| Lupin | 110,193 | 20.55 | 27,488 | 19.98% | 5,345 | 66.98 |
| Mankind Pharma | 103,455 | 52.96 | 14,278 | 12.03% | 1,750 | 59.48 |
| Aurobindo Pharma | 90,058 | 25.68 | 33,385 | 3.21% | 3,376 | 65.10 |
| Laurus Labs | 80,476 | 91.20 | 6,868 | 22.01% | 890 | 70.64 |
Concord Drugs Company Announcements - News Screener
Screen CONCORD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-07-02 | Closure of Trading Window | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Financial Results For Year Ending 31St March2026 | - |
| 2026-05-27 | Board Meeting Outcome for Approval Of Financial Results | - |
| 2026-05-27 | Financial Results For Period Ended 31St March2026 | - |
| 2026-05-27 | Financial Results For Period Ended 31St March2026 | - |
| 2026-05-18 | Board Meeting Intimation for Audited Results For Year Ending 31.03.2026 | - |
| 2026-05-06 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-10 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-10 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-16 | General Update | - |
| 2026-02-14 | Financial Results For Quarter Ended 31St Dec2025 | - |
| 2026-02-14 | Board Meeting Outcome for Out Come Of Board Meetings | - |
| 2026-02-14 | Reconstitution Of Committees | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Retirement | - |
| 2026-02-02 | Board Meeting Intimation for Quarterly Results | - |